Journal Club Review: Pharmacokinetic Aspects of the Two Novel Oral Drugs - Charles Ryan

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide 
Guillemette E. Benoist, Rianne J. Hendricks, Peter F. A. Mulders, Winald R. Gerritsen, Diederik M. Somford, Jack A. Schalken, Inge M. van Oort, David M. Burger, Nielka P. van Erp

In this Journal Club presentation, Dr. Charles Ryan's key points include how an understanding of the pharmacology of abiraterone and enzalutamide can guide rational therapeutic decision-making based on patient-specific characteristics.  In addition, the drug-drug interactions, bioavailability and dosage that should be recognized in order to optimize treatment in patients with mCRPC.  

Read the Abstract

Biography:

Charles J. Ryan